Leonardo Vieira Neto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3159246/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	No association between psychiatric symptoms and doses of anabolic steroids in a cohort of male and female bodybuilders. Drug Testing and Analysis, 2022, 14, 1079-1088.	1.6	9
2	Lower bone density and microarchitecture alterations in HIVâ€infected Brazilian men aged 50 years and older are associated with estradiol levels. Clinical Endocrinology, 2022, 97, 142-149.	1.2	1
3	Cortisol level after dexamethasone suppression test in patients with non-functioning adrenal incidentaloma is positively associated with the duration of reactive hyperemia response on microvascular bed. Journal of Endocrinological Investigation, 2021, 44, 609-619.	1.8	6
4	Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids. Drug Testing and Analysis, 2021, 13, 197-202.	1.6	7
5	Colonic tuberculosis presenting as intestinal subocclusion in a patient with neuroendocrine tumor: a case report. AME Case Reports, 2021, 5, 36-36.	0.2	1
6	Adrenal incidentaloma as a novel independent predictive factor for periodontitis. Journal of Endocrinological Investigation, 2021, 44, 2455-2463.	1.8	5
7	Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density. Archives of Endocrinology and Metabolism, 2021, 65, 505-511.	0.3	2
8	The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature. Journal of Endocrinological Investigation, 2020, 43, 1531-1542.	1.8	18
9	Bone Evaluation by High-Resolution Peripheral Quantitative Computed Tomography in Patients With Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2726-e2737.	1.8	8
10	Multiple endocrine neoplasia type 1 in patients with gastroenteropancreatic neuroendocrine tumors: An opportunity for early diagnosis and appropriate management. Molecular and Clinical Oncology, 2020, 13, 4.	0.4	3
11	Adrenal Venous Sampling in Primary Aldosteronism: The Usefulness of Contralateral Suppression Index. Case Reports in Medicine, 2019, 2019, 1-4.	0.3	2
12	Limitations of Basal Cortisol in the Diagnosis of Cushing Syndrome. AACE Clinical Case Reports, 2019, 5, e91-e94.	0.4	4
13	<i>Twist1</i> Correlates With Epithelial-Mesenchymal Transition Markers <i>Fibronectin</i> and <i>Vimentin</i> in Adrenocortical Tumors. Anticancer Research, 2019, 39, 173-175.	0.5	11
14	Evaluation of body composition using dual-energy X-ray absorptiometry in patients with non-functioning adrenal incidentalomas and an intermediate phenotype: Is there an association with metabolic syndrome?. Journal of Endocrinological Investigation, 2019, 42, 797-807.	1.8	13
15	Impact of Weight Loss With Intragastric Balloon on Bone Density and Microstructure in Obese Adults. Journal of Clinical Densitometry, 2019, 22, 279-286.	0.5	6
16	Vitamin D deficiency is associated with cortical bone loss and fractures in the elderly. European Journal of Endocrinology, 2019, 181, 509-517.	1.9	16
17	Vitamin D Deficiency and Its Influence on Bone Metabolism and Density in a Brazilian Population of Healthy Men. Journal of Clinical Densitometry, 2018, 21, 91-97.	0.5	8
18	Pituitary Hyperplasia in a Female Patient with a Severe Childhood Abuse History. Journal of Trauma and Dissociation, 2018, 19, 136-142.	1.0	0

#	Article	IF	CITATIONS
19	The presence of nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and severity, and is associated with cortisol levels after dexamethasone suppression test. Journal of Human Hypertension, 2018, 32, 3-11.	1.0	23
20	Inhaled glucocorticoids are associated with vertebral fractures in COPD patients. Journal of Bone and Mineral Metabolism, 2018, 36, 454-461.	1.3	15
21	Nonfunctioning adrenal incidentaloma: A novel predictive factor for metabolic syndrome. Clinical Endocrinology, 2018, 89, 586-595.	1.2	31
22	A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 2018, 62, 87-105.	0.3	3
23	Gastrinoma of Cystic Duct: A Rare Association With Multiple Endocrine Neoplasia Type 1. Journal of Clinical Medicine Research, 2018, 10, 843-847.	0.6	1
24	A Novel TP53 Mutation Associated with TWIST1 and SIP1 Expression in an Aggressive Adrenocortical Carcinoma. Endocrine Pathology, 2017, 28, 326-331.	5.2	9
25	Periodontal profile and radiographic characterization of the jaws in a patient with autosomal dominant osteopetrosis. Endocrinology, Diabetes and Metabolism Case Reports, 2017, 2017, .	0.2	1
26	Glycemic Control Rate in Type 2 Diabetes Mellitus Patients at a Public Referral Hospital in Rio de Janeiro, Brazil: Demographic and Clinical Factors. Journal of Endocrinology and Metabolism, 2017, 7, 61-67.	0.1	4
27	Role of Imaging Tests for Preoperative Location of Pathologic Parathyroid Tissue in Patients with Primary Hyperparathyroidism. Endocrine Practice, 2016, 22, 1062-1067.	1.1	10
28	Recommendations of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism for the diagnosis of Cushing's disease in Brazil. Archives of Endocrinology and Metabolism, 2016, 60, 267-286.	0.3	14
29	A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 2016, 60, 374-390.	0.3	20
30	Bone Mineral Density and Microarchitecture in Patients With Autosomal Dominant Osteopetrosis: A Report of Two Cases. Journal of Bone and Mineral Research, 2016, 31, 657-662.	3.1	27
31	Assessment of Predictive Response Factors to Intragastric Balloon Therapy for the Treatment of Obesity. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2016, 26, 168-173.	0.5	2
32	Recurrence and mortality prognostic factors in childhood adrenocortical tumors: Analysis from the Brazilian National Institute of Cancer experience. Pediatric Hematology and Oncology, 2016, 33, 248-258.	0.3	11
33	A novel approach for the automated segmentation and volume quantification of cardiac fats on computed tomography. Computer Methods and Programs in Biomedicine, 2016, 123, 109-128.	2.6	54
34	Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients. Journal of Bone and Mineral Metabolism, 2016, 34, 417-421.	1.3	28
35	Bone density and microarchitecture in endogenous hypercortisolism. Clinical Endocrinology, 2015, 83, 468-474.	1.2	36
36	Insulin-like growth factor (IgF)-I, IgF binding protein-3, and prostate cancer: correlation with gleason score. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 110-115.	0.7	10

#	Article	IF	CITATIONS
37	Adverse effects of glucocorticoids: coagulopathy. European Journal of Endocrinology, 2015, 173, M11-M21.	1.9	72
38	Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4447-4455.	1.8	51
39	Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation,) Tj ETQq1 1 0.784	314 rgBT / 3.2	Overlock 10
40	Pituitary Tumor Management in Pregnancy. Endocrinology and Metabolism Clinics of North America, 2015, 44, 181-197.	1.2	25
41	Ipilimumab-induced hypophysitis: review of the literature. Journal of Endocrinological Investigation, 2015, 38, 1159-1166.	1.8	56
42	Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and <i>in vivo</i> response to cabergoline therapy. Clinical Endocrinology, 2015, 82, 739-746.	1.2	49
43	Rotation thromboelastometry and the hypercoagulable state in <scp>C</scp> ushing's syndrome. Clinical Endocrinology, 2014, 81, 657-664.	1.2	16
44	Prevalence of obstructive sleep apnea in patients with prolactinoma before and after treatment with dopamine agonists. Pituitary, 2014, 17, 441-449.	1.6	25
45	Efficacy of medical treatment in <scp>C</scp> ushing's disease: a systematic review. Clinical Endocrinology, 2014, 80, 1-12.	1.2	59
46	Giant prolactinomas: the therapeutic approach. Clinical Endocrinology, 2013, 79, 447-456.	1.2	91
47	Vertebral Fracture Assessment in Acromegaly. Journal of Clinical Densitometry, 2013, 16, 238-243.	0.5	48
48	Functional evaluation of the joints in acromegalic patients and associated factors. Clinical Rheumatology, 2013, 32, 991-998.	1.0	32
49	Acromegaly Has a Negative Influence on Trabecular Bone, But Not on Cortical Bone, as Assessed by High-Resolution Peripheral Quantitative Computed Tomography. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1734-1741.	1.8	90
50	Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. European Journal of Endocrinology, 2013, 169, 217-223.	1.9	55
51	The Role of Temozolomide in the Treatment of a Patient With a Pure Silent Pituitary Somatotroph Carcinoma. Endocrine Practice, 2013, 19, e145-e149.	1.1	21
52	Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. Journal of Endocrinological Investigation, 2013, 36, 38-43.	1.8	55
53	AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocrine-Related Cancer, 2012, 19, L25-L29.	1.6	100
54	Association of Dengue Hemorrhagic Fever With Multiple Risk Factors for Pituitary Apoplexy. Endocrine Practice, 2012, 18, e97-e101.	1.1	22

#	Article	IF	CITATIONS
55	Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry. Journal of Endocrinological Investigation, 2012, 35, 580-4.	1.8	10
56	Aortic root ectasia in patients with acromegaly: experience at a single center. Clinical Endocrinology, 2011, 75, 495-500.	1.2	28
57	Sellar and suprasellar mixed germ cell tumor mimicking a pituitary adenoma. Pituitary, 2011, 14, 345-350.	1.6	16
58	Hematologic neoplasias and acromegaly. Pituitary, 2011, 14, 377-381.	1.6	7
59	Impact of <i>gsp</i> Oncogene on the mRNA Content for Somatostatin and Dopamine Receptors in Human Somatotropinomas. Neuroendocrinology, 2011, 93, 40-47.	1.2	19
60	Low Aryl Hydrocarbon Receptor-Interacting Protein Expression Is a Better Marker of Invasiveness in Somatotropinomas than Ki-67 and p53. Neuroendocrinology, 2011, 94, 39-48.	1.2	69
61	Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly. Osteoporosis International, 2010, 21, 2019-2025.	1.3	26
62	Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1931-1937.	1.8	120
63	Utility of [18F] fluoro-2-deoxy-d-glucose positron emission tomography in the localization of ectopic ACTH-secreting tumors. Pituitary, 2009, 12, 380-383.	1.6	19
64	Prevalence of discordant CH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR®. Growth Hormone and IGF Research, 2008, 18, 389-393.	0.5	53
65	Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology, 2008, 158, 295-303.	1.9	160
66	Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LARA® responsiveness in acromegaly. Arquivos Brasileiros De Endocrinologia E Metabologia, 2008, 52, 1288-1295.	1.3	13
67	Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR®. Growth Hormone and IGF Research, 2007, 17, 77-81.	0.5	4
68	Prospective evaluation of pregnant women with hypothyroidism: Implications for treatment. Gynecological Endocrinology, 2007, 23, 138-141.	0.7	4
69	Acromegaly Secondary to Growth Hormone-releasing Hormone Secreted by an Incidentally Discovered Pheochromocytoma. Endocrine Pathology, 2007, 18, 46-52.	5.2	39
70	An immunofluorescence test for diagnosis of ophthalmic herpes in a mouse corneal model. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2007, 49, 87-92.	0.5	2
71	Osteosarcoma and acromegaly: A case report and review of the litereture. Journal of Endocrinological Investigation, 2006, 29, 1006-1011.	1.8	17
72	Angina pectoris em paciente com hipertireoidismo e coronárias angiograficamente normais. Arquivos Brasileiros De Cardiologia, 2006, 87, e176-e178.	0.3	2